Timothy Morris, MD
Pulmonary Disease · San Diego, CANPI 1134206709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,125 of the $8,302 with a category attached, or 61.7%. Fisher & Paykel Healthcare Inc accounts for 68.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $6,485 and has fallen 92.8% since, to $467 in 2025.
Across 36 payments — averaging $230.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fisher & Paykel Healthcare Inc$6K
- Inari Medical, Inc.$1K
- Penumbra, Inc.$330
- Boston Scientific$272
- Stryker$136
- AstraZeneca$102
- plus $418 from 7 others
Across 37 payments — averaging $8201.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$275K
- Daiichi Sankyo Inc.$29K
What the payments were for
- Speaking & faculty fees$5,12562%
- Travel & lodging$87511%
- Food & beverage$2,30228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fisher & Paykel Healthcare Inc | 11 | $5,655 |
| Inari Medical, Inc. | 9 | $1,389 |
| Penumbra, Inc. | 4 | $330 |
| Boston Scientific | 2 | $272 |
| Stryker | 1 | $136 |
| AstraZeneca | 1 | $102 |
| Intuitive Surgical | 1 | $99 |
| American Regent | 1 | $94 |
| Bayer | 2 | $85 |
| Covidien LP | 1 | $72 |
| Resmed Corp | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,302 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $85,330 |
| XareltoRivaroxaban | 12 | $8,191 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Shari BrazinskySan Diego$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.